Clinical Trial

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Name: A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors — clinical trial record (NCT07036185)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.

Trial Details

NCT Number	NCT07036185
Lead Sponsor	Shanghai Bao Pharmaceuticals Co., Ltd.
Conditions	Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Bile Duct Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment	66 participants
Start Date	2025-06-24
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-25